Information for the public
Obinutuzumab (Gazyvaro), given with a drug called chlorambucil, is recommended as a possible treatment for adults with untreated chronic lymphocytic leukaemia only if:
they have other conditions that make full-dose fludarabine unsuitable for them and
bendamustine is not suitable for them.
Obinutuzumab should be available on the NHS within 3 months of the guidance being issued.
If you are not eligible for treatment as described above, you should be able to continue taking obinutuzumab (with chlorambucil) until you and your doctor decide it is the right time to stop.